Medtronic (NYSE:MDT) Stock Price Down 0.5% - Here's What Happened

Medtronic plc (NYSE:MDT - Get Free Report)'s stock price was down 0.5% during mid-day trading on Friday . The stock traded as low as $81.88 and last traded at $82.31. Approximately 909,712 shares were traded during mid-day trading, a decline of 85% from the average daily volume of 6,224,465 shares. The stock had previously closed at $82.73.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on MDT shares. Wells Fargo & Company cut their target price on shares of Medtronic from $106.00 to $98.00 and set an "overweight" rating for the company in a research note on Wednesday, November 20th. JPMorgan Chase & Co. reduced their price target on Medtronic from $99.00 to $96.00 and set a "neutral" rating on the stock in a research report on Friday, November 15th. UBS Group upgraded Medtronic from a "sell" rating to a "neutral" rating and upped their target price for the company from $76.00 to $90.00 in a report on Thursday, August 15th. Royal Bank of Canada upgraded shares of Medtronic from a "sector perform" rating to an "outperform" rating and boosted their price target for the stock from $98.00 to $105.00 in a research report on Thursday, October 10th. Finally, Citigroup increased their price objective on shares of Medtronic from $85.00 to $92.00 and gave the stock a "neutral" rating in a research report on Tuesday, October 1st. One analyst has rated the stock with a sell rating, nine have issued a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, Medtronic has an average rating of "Hold" and a consensus price target of $95.27.

Medtronic Price Performance

The company has a debt-to-equity ratio of 0.51, a current ratio of 1.84 and a quick ratio of 1.39. The firm has a market capitalization of $105.67 billion, a PE ratio of 25.17, a P/E/G ratio of 2.35 and a beta of 0.82. The business's 50 day moving average is $87.77 and its two-hundred day moving average is $84.99.

Medtronic (NYSE:MDT - Get Free Report) last posted its quarterly earnings data on Tuesday, November 19th. The medical technology company reported $1.26 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.25 by $0.01. Medtronic had a net margin of 13.00% and a return on equity of 13.79%. The company had revenue of $8.40 billion during the quarter, compared to the consensus estimate of $8.27 billion. During the same period in the previous year, the firm posted $1.25 EPS. The firm's revenue was up 5.2% compared to the same quarter last year. As a group, research analysts anticipate that Medtronic plc will post 5.45 EPS for the current year.

Medtronic Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 10th. Shareholders of record on Friday, December 27th will be paid a $0.70 dividend. This represents a $2.80 annualized dividend and a yield of 3.40%. The ex-dividend date is Friday, December 27th. Medtronic's dividend payout ratio is presently 85.63%.

Hedge Funds Weigh In On Medtronic

A number of large investors have recently bought and sold shares of the stock. Olstein Capital Management L.P. boosted its holdings in shares of Medtronic by 19.2% during the third quarter. Olstein Capital Management L.P. now owns 87,000 shares of the medical technology company's stock worth $7,833,000 after purchasing an additional 14,000 shares during the period. Y Intercept Hong Kong Ltd grew its position in Medtronic by 322.6% in the 3rd quarter. Y Intercept Hong Kong Ltd now owns 73,593 shares of the medical technology company's stock worth $6,626,000 after purchasing an additional 56,178 shares during the period. Ferguson Wellman Capital Management Inc. purchased a new stake in Medtronic during the 3rd quarter valued at $9,486,000. Harvest Portfolios Group Inc. lifted its holdings in shares of Medtronic by 6.5% during the 3rd quarter. Harvest Portfolios Group Inc. now owns 689,131 shares of the medical technology company's stock valued at $62,042,000 after buying an additional 42,112 shares during the period. Finally, Soltis Investment Advisors LLC boosted its stake in shares of Medtronic by 30.0% in the 3rd quarter. Soltis Investment Advisors LLC now owns 88,110 shares of the medical technology company's stock worth $7,933,000 after buying an additional 20,352 shares during the last quarter. 82.06% of the stock is owned by hedge funds and other institutional investors.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.